Masimo price target raised to $148 from $125 at Stifel

Stifel raised the firm’s price target on Masimo to $148 from $125 and keeps a Hold rating on the shares after the company announced that the board has authorized management to evaluate a possible separation of its consumer business. Friday’s announcement is “very roughly a year ahead of our expectations for this review,” says the firm, which adds that it is “inclined to think MASI shares will react positively to the Consumer separation review development” and the potential to return Masimo’s sole focus to the Healthcare franchise’s innovation pipeline, profitability, and competitive position.